02196 FOSUN PHARMA
- 13.520
- +0.020+0.15%
FOSUN PHARMA News
Express News | A Perspective on Listed Companies' Quarterly Shareholder Lists Cyclical industries are popular among institutions
The quarterly adjustment of the MSCI Index excludes 15 Hong Kong stocks. The effective date is scheduled for early June
① Which individual stocks will MSCI China adjust quarterly? ② How much impact does the MSCI Index have on the market?
Futu Morning Post | The three major US stock indices hit new highs! Ultramicrocomputers and Nvidia explode together
“New Federal Reserve News Agency”: The Federal Reserve may still not cut interest rates until September; “Big Short” Michael Burry took a heavy gold position in the first quarter.
MSCI Global Standard Index: Hong Kong stocks include Hisense Home Appliances and Minmetals Resources, excluding 17 such as Fosun Pharma
Gelonghui, May 15 | In the early morning of May 15, Beijing time, the international index compilation company MSCI announced the quarterly index adjustment results for May 2024. The adjustment results will take effect after closing on May 31, 2024. In this adjustment, 42 new shares were added to the MSCI Global Standard Index, including 2 Hong Kong shares (Hisense Home Appliances, Minmetals Resources); 121 stocks were removed at the same time, including 17 Hong Kong stocks (Zaiding Pharmaceutical, Jiantao Group, Country Garden Service, Zhongan Online, Kangzhe Pharmaceutical, Yuexiu Real Estate, Oriental Selection, China Cinda, Sany International, Air China, Global Healthcare,
Fosun Pharma Unit Fosun Health to Receive Capital Injection From Foshan Chanxi City Investment
Fosun Health, a unit of Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196), will receive a capital injection from Foshan Chanxi City Investment, according to a Wednesday filing on the Shangh
Fosun Pharmaceutical (600196): Continuing to promote innovation and transformation
Core view: *Unless otherwise specified, the currency used in the report is RMB. The company released the 2023 annual report and 2024 quarterly report: 2023 revenue of 41.4 billion yuan (-5.81% YoY), net profit to mother
Fuhong Hanlin, an affiliate of Fosun Pharmaceutical (600196.SH), was approved for drug clinical trials
Fosun Pharmaceutical (600196.SH) announced that Shanghai Fuhong Hanlin Biotechnology Co., Ltd., a holding subsidiary of the company...
Fosun Pharmaceutical (600196.SH): Holding subsidiary Fosun Health signs capital increase and share expansion agreement
Gelonghui, May 14, 丨 Fosun Pharmaceutical (600196.SH) announced that according to the “Cooperation Agreement” reached between Fosun Health, its holding subsidiary, and the Chancheng District People's Government of Foshan City on February 23, 2024, the Company's holding subsidiary Fosun Health signed a “Capital Increase Agreement” with Foshan Chanxi City Investment on May 14, 2024. According to the “Capital Increase Agreement”, Foshan Chanxi City Investment plans to designate entities (including funds, holding companies or other entities) to invest RMB 30,000 million in a pre-investment valuation of RMB 10.2 billion and pledge Fosun Health's additional registered capital of RMB 156.17 million (i.e.
Express News | Fosun Pharmaceutical: HLX78, a holding subsidiary, was approved for drug clinical trials
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | The first Yikaida CAR-T cell treatment center in Macau settled in Jinghu Hospital
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets
China's medical products administrator granted Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) unit Shanghai Chongqing Yaoyou Pharmaceutical marketing registration approval for its aripip
Fosun Pharmaceutical (02196.HK) plans to hold 2023 and 2024 first quarter results briefings on May 17
Gelonghui, May 9, 丨 Fosun Pharmaceutical (02196.HK) announced that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”) will disclose its 2023 annual report on March 27, 2024, and the first quarter report of 2024 on April 30, 2024. In order to facilitate investors to have a more comprehensive and in-depth understanding of the Group's (that is, the company and holding subsidiaries/units, the same below) results and operations for 2023 and the first quarter of 2024, the company is scheduled to be held on May 17, 2024 from 15:00-16:30 p.m.
Fosun Pharmaceuticals (02196) guarantees its holding subsidiary
Fosun Pharmaceutical (02196) announced that the company intends to apply for the principal amount of the holding subsidiary Fosun Antekin from the Bank of Chengdu...
Fosun Pharmaceutical (02196): Application for marketing registration of aripiprazole oral tablets for the treatment of schizophrenia was approved by the State Drug Administration
Fosun Pharmaceutical (02196) announced that the marketing registration application for aripiprazole oral tablets (hereinafter referred to as the “new drug”) independently developed by the company's holding subsidiary Shanghai Chongqing Yaoyou Pharmaceutical Co., Ltd. for the treatment of schizophrenia was recently approved by the China Drug Administration.
Express News | Fosun Pharmaceuticals announced that its holding subsidiary was approved for the registration of aripiprazole oral tablets.
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets
The US Food and Drug Administration granted clinical trial approval to Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) for unit Shanghai Henlius Biotechnology's HLX22 tablets indicated fo
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Fosun Pharmaceutical (02196.HK) has yet to repurchase shares
Gelonghui, May 6, 丨 Fosun Pharmaceutical (02196.HK) issued an announcement. From March 26, 2024 (that is, the date the board of directors reviewed and approved the repurchase plan) to April 30, 2024, the company has not yet repurchased shares under the repurchase plan.
Analysis
Price Target
No Data
